Molecular basis for the interaction of histamine with the histamine H2 receptor.
We undertook these studies to characterize the molecular basis of the interaction of histamine with the H2 receptor. Key areas of homology in the structures of the histamine H2 and beta 2 adrenergic receptor suggested specific transmembrane amino acids that might be important for binding of histamine. A third transmembrane aspartic acid of the histamine receptor (Asp98), thought to serve as a counter anion that interacts with the cationic amine moiety of histamine, was mutated to Asn98, and the mutated receptor was expressed in Hepa cells. Removal of the negatively charged amino acid abolished both binding of the H2 receptor antagonist [methyl-3H]tiotidine and histamine stimulated increases in cellular cAMP content. Mutation of a fifth transmembrane aspartic acid (Asp186) to Ala186 or Asn186 by itself or in conjunction with mutation of another fifth transmembrane amino acid (Thr190 to Ala190) resulted in a loss of [methyl-3H] tiotidine binding, although the generation of cAMP in response to histamine was maintained. The histamine receptor with only a Thr190 to Ala190 or Cys190 mutation retained the ability to bind [methyl-3H]tiotidine, but both the affinity and efficacy of binding were reduced. These data lead us to propose a model for histamine binding in which Asp98 is essential for histamine binding and action, Asp186 defines H2 selectivity, and Thr190 is important in establishing the kinetics of histamine binding, but is not essential for H2 selectivity.
Gantz
I
I
Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109-0368.
DelValle
J
J
Wang
L D
LD
Tashiro
T
T
Munzert
G
G
Guo
Y J
YJ
Konda
Y
Y
Yamada
T
T
D000595:Amino Acid Sequence; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002927:Cimetidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D003001:Cloning, Molecular; D000242:Cyclic AMP / Q000378:metabolism; D004285:Dogs; D006632:Histamine / Q000378:metabolism* / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000378:metabolism; D007700:Kinetics; D008114:Liver Neoplasms, Experimental; D016297:Mutagenesis, Site-Directed; D051381:Rats; D011970:Receptors, Histamine H2 / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured
D006635:Histamine H2 Antagonists; D011970:Receptors, Histamine H2; D002927:Cimetidine; D006632:Histamine; D000242:Cyclic AMP; C023990:tiotidine